Lipidtherapie in der Praxis - was kann man, muss man, soll man?:
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Format: | Buch |
| Sprache: | German |
| Veröffentlicht: |
Bremen ; London ; Boston
UNI-MED Verlag AG
2017
|
| Ausgabe: | 2. Auflage |
| Schriftenreihe: | UNI-MED science
|
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis Inhaltsverzeichnis |
| Beschreibung: | 79 Seiten Illustrationen, Diagramme 25 cm |
| ISBN: | 9783837415438 |
Internformat
MARC
| LEADER | 00000nam a2200000 c 4500 | ||
|---|---|---|---|
| 001 | BV045157516 | ||
| 003 | DE-604 | ||
| 005 | 20181105 | ||
| 007 | t | ||
| 008 | 180830s2017 a||| |||| 00||| ger d | ||
| 015 | |a 17,A27 |2 dnb | ||
| 016 | 7 | |a 1135208425 |2 DE-101 | |
| 020 | |a 9783837415438 |c Festeinband : EUR 29.80 (DE) |9 978-3-8374-1543-8 | ||
| 035 | |a (OCoLC)991852773 | ||
| 035 | |a (DE-599)DNB1135208425 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a ger | |
| 049 | |a DE-578 | ||
| 082 | 0 | |a 616.399706 |2 22/ger | |
| 084 | |a WD 200.5 |2 nlm | ||
| 084 | |a 610 |2 sdnb | ||
| 100 | 1 | |a Sinzinger, Helmut |d 1948-2020 |0 (DE-588)115161708 |4 aut |4 edt | |
| 240 | 1 | 0 | |a Lipidtherapie in der Praxis |
| 245 | 1 | 0 | |a Lipidtherapie in der Praxis - was kann man, muss man, soll man? |c Prof. Dr. Helmut F. Sinzinger, Prof. Dr. Kurt Derfler, Prim. Priv.-Doz. Dr. Robert Berent ; unter Mitarbeit von Prof. Dr. Stylianos Kapiotis [und 5 andere] |
| 250 | |a 2. Auflage | ||
| 264 | 1 | |a Bremen ; London ; Boston |b UNI-MED Verlag AG |c 2017 | |
| 300 | |a 79 Seiten |b Illustrationen, Diagramme |c 25 cm | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 0 | |a UNI-MED science | |
| 650 | 0 | 7 | |a Lipidstoffwechselstörung |0 (DE-588)4035876-8 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Therapie |0 (DE-588)4059798-2 |2 gnd |9 rswk-swf |
| 689 | 0 | 0 | |a Lipidstoffwechselstörung |0 (DE-588)4035876-8 |D s |
| 689 | 0 | 1 | |a Therapie |0 (DE-588)4059798-2 |D s |
| 689 | 0 | |5 DE-604 | |
| 700 | 1 | |a Derfler, Kurt |e Verfasser |0 (DE-588)1170621104 |4 aut | |
| 700 | 1 | |a Berent, Robert |e Verfasser |0 (DE-588)1170621554 |4 aut | |
| 856 | 4 | 2 | |m B:DE-101 |q application/pdf |u http://d-nb.info/1135208425/04 |3 Inhaltsverzeichnis |
| 856 | 4 | 2 | |m DNB Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=030547079&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-030547079 | ||
Datensatz im Suchindex
| _version_ | 1804178834738642944 |
|---|---|
| adam_text | INHALTSVERZEICHNIS
3.1.
3.2.
3.3.
3.3.1.
3.3.2.
3.3.3.
3.4.
3.5.
3.6.
4.1.
4.2.
5.1.
5.2.
5.3.
5.4.
5.5.
5.6.
5.7.
5.7.1.
5.7.2.
5.7.3.
5.7.4.
5.7.5.
5.8.
5.9.
5.10.
5.11.
5.11.1.
5.11.2.
5.12.
5.13.
5.13.1.
5.13.2.
5.13.3.
5.14.
5.15.
EINLEITUNG 14
ATHEROSKLEROTISCHE HOCHRISIKOLAESIONEN 15
RISIKOFAKTOREN 17
NICHT BEEINFLUSSBARE RISIKOFAKTOREN
(RF)..................................................................................................17
BEEINFLUSSBARE
RISIKOFAKTOREN......................................................................................................................17
BEDEUTUNG DER RISIKOFAKTOREN FUER UNTERSCHIEDLICHE ATHEROSKLEROTISCHE
MANIFESTATIONEN
___
17
KORONARE HERZKRANKHEIT
(KHK).........................................................................................................................17
PERIPHERE ARTERIELLE VERSCHLUSSKRANKHEIT
(PAVK).........................................................................................17
ZEREBROVASKULAERE KRANKHEIT
(ZVK)...................................................................................................................17
VERTEILUNG DER
RISIKOFAKTOREN........................................................................................................................18
EINSCHAETZUNG DES INDIVIDUELLEN
RISIKOS....................................................................................................18
MASSENSTRATEGIE VS.
INDIVIDUALSTRATEGIE....................................................................................................18
SCREENING 20
ALLGEMEINES.......................................................................................................................................................20
LIPIDSCREENING - WARUM, WAS, WANN, WER, WIE,
WO?..............................................................................20
FETTSTOFFWECHSELSTOERUNGEN - DIAGNOSE UND ZIELPARAMETER 22
DEFINITION.............................................................................................................................................................22
PATHOPHYSIOLOGIE.............................................................................................................................................22
ALLGEMEINE
DIAGNOSTIK...................................................................................................................................22
KLINISCHE
ZEICHEN.............................................................................................................................................23
PRAEDISPONIERENDE
KOERPERSTELLEN..................................................................................................................23
RELEVANTE
LABORDIAGNOSTIK...........................................................................................................................23
ATHEROGENE RISIKOFAKTOREN BEI METABOLISCHEM SYNDROM
..................................................................
24
ATHEROGENE
FETTSTOFFWECHSELSTOERUNG...........................................................................................................24
INSULINRESISTENZ....................................................................................................................................................25
PROTHROMBOTISCHER
ZUSTAND............................................................................................................................25
PROINFLAMMATORISCHER
ZUSTAND........................................................................................................................26
ANDERE
RISIKOFAKTOREN.......................................................................................................................................26
ROUTINEDIAGNOSTIK...........................................................................................................................................26
BEFUNDINTERPRETATION ZUR ABSCHAETZUNG DES KORONAREN
RISIKOS.........................................................26
HYPERTRIGLYCERIDAEMIE (HTG) UND
LABORANALYTIK......................................................................................26
REZEPTORDIAGNOSTIK.........................................................................................................................................26
LDL-REZEPTOR......................................................................................................................................................26
SCAVENGER-REZEPTOR..........................................................................................................................................
27
DNA-DIAGNOSTIK...............................................................................................................................................27
HYPERCHOLESTERINAEMIE
(HC)...........................................................................................................................27
GEWOEHNLICHE ( POLYGENE )
HC........................................................................................................................27
GEMISCHTE (ATHEROGENE)
DYSLIPIDAEMIE.........................................................................................................27
FAMILIAERE HYPERCHOLESTERINAEMIE
(FH).............................................................................................................27
SOG. FAMILIAL DEFECTIVE
APOB .....................................................................................................................28
REMNANT-HYPERLIPIDAEMIE ( HYPERLIPIDAEMIE TYP
III )............................................................................28
5.16. FAMILIAER-KOMBINIERTE
HYPERLIPIDAEMIE.........................................................................................................28
5.17. CHYLOMIKRONAEMIE-SYNDROM (TG 1000 M
G/DL)......................................................................................28
5.18. FAMILIAERE
HTG.....................................................................................................................................................28
5.19. FAMILIAERE
HYPERALPHALIPOPROTEINAEMIE......................................................................................................28
5.20. FAMILIAERE
HYPOALPHALIPOPROTEINAEMIE........................................................................................................29
5.21. EINTEILUNG DER
HLP.............................................................................................................................................29
5.21.1. EINTEILUNG NACH
PHAENOTYP.................................................................................................................................29
5.21.2. EINTEILUNG NACH
GENOTYP..................................................................................................................................29
5.21.3. EINTEILUNG NACH
LIPIDSTATUS...............................................................................................................................30
5.22. SEKUNDAERE
HYPERLIPIDAEMIE............................................................................................................................30
M RICHTWERTE 31
6.1.
ZIELWERTE.............................................................................................................................................................31
6.2. LIPIDPARAMETER UND IHRE
BEDEUTUNG..........................................................................................................31
6.3. DIAGNOSTISCHE
GRUNDPRINZIPIEN..................................................................................................................32
6.3.1. GESAMT-CHOLESTERIN
(CH)..................................................................................................................................32
6.3.2. TRIGLYCERIDE
(TG)...................................................................................................................................................32
6.3.3.
HDL-CH.................................................................................................................................................................
32
6.3.4.
LDL-CH.................................................................................................................................................................
33
6.3.4.1. PRAEVALENZ KLEINER, DICHTER
LDL-CH-PARTIKEL............................. 33
6.3.4.2. MECHANISMEN DER
ATHEROGENITAET..........................................................................................................................34
6.3.43.
MODIFIKATION...........................................................................................................................................................34
6.3.5.
CHYLOMIKRONEN....................................................................................................................................................34
6.3.6.
VLDL-CH................................................................................................................................................................34
6.3.7.
IDL-CH...................................................................................................................................................................34
6.3.8.
LP(A).......................................................................................................................................................................34
6.3.9.
NON-HDL-CH........................................................................................................................................................35
6.3.10.
LIPOPROTEINE.........................................................................................................................................................35
6.3.11.
APOLIPOPROTEINE.................................................................................................................................................35
6.3.12.
LIPOPROTEINKLASSIFIKATION.................................................................................................:
.............................
35
6.4. BERECHNETE PARAMETER UND
QUOTIENTEN.....................................................................................................36
6.4.1. CH : HDL-CH (ATHEROGENER
INDEX)....................................................................................................................36
6.4.2. LDL-CH :
HDL-CH.................................................................................................................................................36
6.4.3. TG : HDL-CH (DIABETOGENER
INDEX).................................................................................................................36
M NICHT-PHARMAKOLOGISCHE BEHANDLUNG DER HYPERLIPIDAEMIE 37
7.1.
PFLANZENSTEROLE.................................................................................................................................................37
7.1.1.
WIRKMECHANISMUS...............................................................................................................................................37
7.2.
SOJAPROTEINE.......................................................................................................................................................37
7.3.
BALLASTSTOFFE.......................................................................................................................................................38
7.4.
OMEGA-3-FETTSAEUREN.......................................................................................................................................38
7.4.1. ANTITHROMBOTISCHE UND ANTIINFLAMMATORISCHE
WIRKUNG.............................................................................39
7.4.2. WIRKUNGEN AUF DEN
FETTSTOFFWECHSEL.............................................................................................................39
7.4.3. ANTIARRHYTHMISCHER
EFFEKT................................................................................................................................39
7.4.4.
CUE
3-FS UND KARDIOVASKULAERES
RISIKO.................................................................................................................39
7.5. GESAETTIGTE
FETTSAEUREN.....................................................................................................................................40
7.6.
TRANSFETTSAEUREN.................................................................................................................................................40
7.7. ERNAEHRUNGSMASSNAHMEN -
ALLGEMEIN........................................................................................................40
7.7.1.
ESSVERHALTEN........................................................................................................................................................40
7.7.2. NORMALES
KOERPERGEWICHT.................................................................................................................................
41
7.7.3. NORMALE
BLUTFETTE...............................................................................................................................................41
7.7.4.
BLUTDRUCK.............................................................................................................................................................41
7.8. ERNAEHRUNGSMASSNAHMEN -
SPEZIELL.............................................................................................................
41
7.8.1. IM
ALTER.................................................................................................................................................................41
7.8.2.
KINDER...................................................................................................................................................................41
7.8.3. RASSENSPEZIFISCHE UND GENETISCHE
FAKTOREN................................................................................................41
7.9. ERNAEHRUNGSMASSNAHMEN -
GESICHERT..........................................................................................................42
7.9.1.
GEWICHT.................................................................................................................................................................42
7.9.2.
BLUTFETTE...............................................................................................................................................................42
7.9.3. AUSWIRKUNGEN AUF
LDL-SENKUNG....................................................................................................................42
7.10. EINIGE
FAUSTREGELN...........................................................................................................................................42
7.11. ERNAEHRUNGSMASSNAHMEN - SPEZIELLE
ERKRANKUNGEN................................................................................42
7.11.1. KLINISCH MANIFESTE
ATHEROSKLEROSE..................................................................................................................42
7.11.2. DIABETES
MELLITUS................................................................................................................................................42
7.12. ERNAEHRUNGSMASSNAHMEN -
VERMUTLICH......................................................................................................42
7.12.1.
BALLASTSTOFFE.........................................................................................................................................................42
7.12.2.
STANOL/STEROLESTER..............................................................................................................................................43
7.12.3.
SOJAPROTEIN.........................................................................................................................................................43
7.12.4.
CO3-FS.....................................................................................................................................................................43
7.12.5. ROTER
REIS.............................................................................................................................................................43
7.12.6.
HOMOCYSTEIN........................................................................................................................................................43
7.12.7.
ANTIOXIDANTIEN.....................................................................................................................................................43
7.12.8. NUESSE (ANGABEN/100
G).....................................................................................................................................43
7.12.9. OBST
(ANGABEN/100G)........................................................................................................................................43
7.13. MASSNAHMEN ZUR STEIGERUNG DES SAETTIGUNGSGEFUEHLS UND ZUR
KALORIENREDUKTION
..........................
44
7.14. GESUNDE BLUTGEFAESSE - RATSCHLAEGE FUER IHRE PATIENTEN
...........................................................................
44
7.15.
DEVISE..................................................................................................................................................................44
7.16.
BEWEGUNG..........................................................................................................................................................
44
7.17.
UEBERGEWICHT.......................................................................................................................................................45
7.18. KANN MAN UEBERGEWICHT
BERECHNEN?.........................................................................................................
46
7.18.1.
BROCA-INDEX.......................................................................................................................................................46
7.16.2. BODY MASS INDEX
(BMI).......................................................................................................................................46
7.18.3.
FETTWAAGE...........................................................................................................................................................46
7.18.4. WAIST/HIP-RATIO
(WHR)........................................................................................................................................46
7.18.5.
FETTVERTEILUNG......................................................................................................................................................46
7.18.6.
BAUCHUMFANG......................................................................................................................................................46
7.18.7. WIE MESSE ICH MEINEN BU
RICHTIG?...................................................................................................................
47
7.19.
DIAETFORMEN........................................................................................................................................................47
7.19.1.
FETT-BETONT.........................................................................................................................................................47
7.19.2.
EIWEISS-BETONT......................................................................................................................................................47
7.19.3.
KOHLENHYDRAT-BETONT.........................................................................................................................................47
7.19.4. TRENN
KOST.............................................................................................................................................................47
7.19.5.
FASTEN...................................................................................................................................................................48
7.19.6.
WUNDERDIAETEN......................................................................................................................................................48
7.19.7.
MISCHKOST.............................................................................................................................................................48
7.19.8. FETTPUNKTKONZEPT NACH H. KRITZ (KRITZ ET AL.
2004)........................................................................................48
PHARMAKOLOGISCHE THERAPIE 50
8.1.
GRUNDREGEL.........................................................................................................................................................50
8.2. STETS IN DIESER
REIHENFOLGE............................................................................................................................50
8.3.
RICHTLINIEN...........................................................................................................................................................50
8.4. ALLGEMEINE
REGELN............................................................................................................................................50
8.5. PHARMAKOTHERAPIE -
UEBERSICHT....................................................................................................................50
8.5.1.
FIBRATE/FIBRATANALOGA.......................................................................................................................................
52
8.5.2. NIKOTINSAEURE (DZT. NICHT MEHR
VERFUEGBAR)......................................................................................................52
8.5.3.
RESORPTIONSHEMMER...........................................................................................................................................53
8.5.3.1. IONENAUSTAUSCHER (HEMMUNG DER
GALLENSAEURERESORPTION)..............................................................................53
8.53.2. SELEKTIVE
CHOLESTERINRESORPTIONSHEMMER..........................................................................................................53
8.5.4. STATINE (SYNONYM: HMG-COA-REDUKTASE-HEMMER, CSE-HEMMER)
.........................................................
53
8.5.5.
KOMBINATIONSTHERAPIE.......................................................................................................................................
54
8.5.6. PROBLEME DER
STATINTHERAPIE............................................................................................................................54
8.5.7.
SECHSERREGEL........................................................................................................................................................54
8.5.8.
EINNAHME..............................................................................................................................................................54
8.5.9. DIE 5 GOLDENEN REGELN DER
STATINTHERAPIE....................................................................................................55
8.5.10. THE EARLIER, THE
RETTER ...............................................................................................................................55
8.5.10.1. STATINTHERAPIE BEI
KINDERN........................................................ 55
8.5.11. THE LOWER, THE
8ETTER .................................................................................................................................55
8.5.12. EVERY OTHER
DAY ............................................................................................................................................55
8.5.13.
HOCHDOSISTHERAPIE..................................................................
55
8.5.14. AUSMASS DER
LDL-CH-SENKUNG.........................................................................................................................56
8.5.15. STATINTHERAPIE BEI
FRAUEN...................................................................................................................................56
8.5.16.
SCHWANGERSCHAFT..................................................................................................................................................56
8.5.17. STATINTHERAPIE BEI ALTEN
MENSCHEN..................................................................................................................56
8.5.17.1. ENTSCHEIDUNGSGRUNDLAGE ZUR STATINTHERAPIE BEI
ALTEN.....................................................................................56
8.5.17.2.
INDIKATION...............................................................................................................................................................56
8.5.17.3.
SPEZIFIKA.................................................................................................................................................................56
8.5.18.
SCHLUESSELSTUDIEN.................................................................................................................................................57
8.5.19.
TRANSPLANTIERTE.....................................................................................................................
57
8.5.20.
PHARMAKOGENETIK...............................................................................................................................................57
8.5.21. ABSETZEN DER
STATINTHERAPIE.............................................................................................................................57
8.5.22.
WIRKMECHANISMEN.............................................................................................................................................57
8.5.23. PLEIOTROPE (NON-LIPID-)
EFFEKTE........................................................................................................................57
8.5.23.1. ANTIOXIDATIVE
WIRKUNG...........................................................................................................................................58
8.5.23.2. ANTIINFLAMMATORISCHE
WIRKUNG............................................................................................................................58
8.5.23.3.
ENDOTHEL.................................................................................................................................................................58
8.5.24.
NIERENFUNKTION....................................................................................................................................................
58
8.5.25. COENZYM Q10 (COQ10) UND SUBSTITUTION
..........................................................................................................58
8.5.26. NEBENWIRKUNGEN DER
STATINE..........................................................................................................................58
8.5.26.1. SCHWERE NW
...........................................................................................................................................................58
8.5.26.2. LEICHTE
NW.............................................................................................................................................................59
8.5.27.
MUSKULATUR............................................................................................................................................................59
8.5.28.
LEBER.....................................................................................................................................................................60
8.5.29. GASTROINTESTINALE
SYMPTOME............................................................................................................................60
8.5.30.
SEHVERMOEGEN......................................................................................................................................................60
8.5.31.
SCHLAFSTOERUNGEN..................................................................................................................................................60
8.5.32.
ARTHROPATHIEN......................................................................................................................................................61
8.5.33. EREKTILE
DYSFUNKTION...........................................................................................................................................61
8.5.34. PERIPHERE
NEUROPATHIE.....................................................................................................................................61
8.5.35. KOGNITIVE
STOERUNGEN.........................................................................................................................................61
8.5.36.
TENDINOPATHIEN..................................................................................................................................................61
8.6. ANDERE
SUBSTANZEN.........................................................................................................................................61
8.7.
PCSK9...................................................................................................................................................................61
8.7.1. BIOLOGISCHE
WIRKUNG.........................................................................................................................................62
8.7.2. WIRKUNGSMECHANISMUS VON
PCSK9.................................................................................................................64
8.7.3. PCSK9 UND
GEFAESSWAND.....................................................................................................................................64
8.7.4. AKTUELLE
STUDIENLAGE.........................................................................................................................................65
8.7.5. SICHERHEIT UND UNERWUENSCHTE N
W
.................................................................................................................67
M LP-APHERESE 69
9.1. LP-APHERESE - INDIKATIONEN, METHODEN UND
ERGEBNISSE......................................................................69
9.2.
WIRKUNGSNACHWEIS...........................................................................................................................................70
9.3.
KLINISCH.................................................................................................................................................................70
9.4. METHODEN ZUR EXTRAKORPORALEN THERAPIE DER HOMOZYGOTEN BZW.
WEITGEHEND
THERAPIERESISTENTEN HETEROZYGOTEN H
C
....................................................................................................70
9.4.1. PLASMAAUSTAUSCH
(PA).........................................................................................................................................70
9.4.2. HEPARIN-INDUZIERTE EXTRAKORPORALE LDL-PRAEZIPITATION (HELP; FA.
BRAUN, MELSUNGEN, DEUTSCHLAND) 70
9.4.3. LDL-IMMUNADSORPTION (LDL-THERASORB, MILTENYI BIOTEC,
DEUTSCHLAND)..............................................71
9.4.4. DEXTRANSULFAT-ADSORPTION / SERUM PLUS VOLLBLUTSYSTEM
(LIPOSORBER; FA. KANEKA, ESCHBORN,
DEUTSCHLAND)........................................................................................................................................................72
9.4.5. DALI-SYSTEM (DIRECT ADSORPTION OF LIPOPROTEINS; FA. FRESENIUS
MEDICAL CARE, KREMS, OESTERREICH). 72
9.5. APPARATIVE AUSRUESTUNG UND
GEFAESSZUGANG......................................... 72
9.5.1.
GEFAESSZUGANG........................................................................................................................................................72
9.6. INDIKATION ZUR LP-APHERESE
.........................................................................................................................
73
9.7. LP-APHERESE -
BEHANDLUNGSBEGINN..........................................................................................................73
9.8. THERAPEUTISCHE EFFIZIENZ /
STOFFWECHSELKONTROLLE..................................................................................74
9.9. THERAPEUTISCHE EFFIZIENZ / (KARDIO-)VASKULAERE
KOMPLIKATIONEN.........................................................74
9.10. NEBENWIRKUNGEN DER
LDL-APHERESE...........................................................................................................
74
9.11. ANDERE (CHIRURGISCHE)
MASSNAHMEN.............................................................................................................75
9.11.1. LEBERTRANSPLANTATION
.......................................................................................................................................75
9.11.2.
ILEUMBYPASS........................................................................................................................................................75
9.12.
ZUSAMMENFASSUNG...........................................................................................................................................75
ABKUERZUNGSVERZEICHNIS 77
YY INDEX 78
|
| any_adam_object | 1 |
| author | Sinzinger, Helmut 1948-2020 Derfler, Kurt Berent, Robert |
| author2 | Sinzinger, Helmut 1948-2020 |
| author2_role | edt |
| author2_variant | h s hs |
| author_GND | (DE-588)115161708 (DE-588)1170621104 (DE-588)1170621554 |
| author_facet | Sinzinger, Helmut 1948-2020 Derfler, Kurt Berent, Robert Sinzinger, Helmut 1948-2020 |
| author_role | aut aut aut |
| author_sort | Sinzinger, Helmut 1948-2020 |
| author_variant | h s hs k d kd r b rb |
| building | Verbundindex |
| bvnumber | BV045157516 |
| ctrlnum | (OCoLC)991852773 (DE-599)DNB1135208425 |
| dewey-full | 616.399706 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.399706 |
| dewey-search | 616.399706 |
| dewey-sort | 3616.399706 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| edition | 2. Auflage |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01970nam a2200457 c 4500</leader><controlfield tag="001">BV045157516</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20181105 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">180830s2017 a||| |||| 00||| ger d</controlfield><datafield tag="015" ind1=" " ind2=" "><subfield code="a">17,A27</subfield><subfield code="2">dnb</subfield></datafield><datafield tag="016" ind1="7" ind2=" "><subfield code="a">1135208425</subfield><subfield code="2">DE-101</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783837415438</subfield><subfield code="c">Festeinband : EUR 29.80 (DE)</subfield><subfield code="9">978-3-8374-1543-8</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)991852773</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DNB1135208425</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">ger</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-578</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.399706</subfield><subfield code="2">22/ger</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">WD 200.5</subfield><subfield code="2">nlm</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">610</subfield><subfield code="2">sdnb</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Sinzinger, Helmut</subfield><subfield code="d">1948-2020</subfield><subfield code="0">(DE-588)115161708</subfield><subfield code="4">aut</subfield><subfield code="4">edt</subfield></datafield><datafield tag="240" ind1="1" ind2="0"><subfield code="a">Lipidtherapie in der Praxis</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Lipidtherapie in der Praxis - was kann man, muss man, soll man?</subfield><subfield code="c">Prof. Dr. Helmut F. Sinzinger, Prof. Dr. Kurt Derfler, Prim. Priv.-Doz. Dr. Robert Berent ; unter Mitarbeit von Prof. Dr. Stylianos Kapiotis [und 5 andere]</subfield></datafield><datafield tag="250" ind1=" " ind2=" "><subfield code="a">2. Auflage</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Bremen ; London ; Boston</subfield><subfield code="b">UNI-MED Verlag AG</subfield><subfield code="c">2017</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">79 Seiten</subfield><subfield code="b">Illustrationen, Diagramme</subfield><subfield code="c">25 cm</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">UNI-MED science</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Lipidstoffwechselstörung</subfield><subfield code="0">(DE-588)4035876-8</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Therapie</subfield><subfield code="0">(DE-588)4059798-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Lipidstoffwechselstörung</subfield><subfield code="0">(DE-588)4035876-8</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Therapie</subfield><subfield code="0">(DE-588)4059798-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Derfler, Kurt</subfield><subfield code="e">Verfasser</subfield><subfield code="0">(DE-588)1170621104</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Berent, Robert</subfield><subfield code="e">Verfasser</subfield><subfield code="0">(DE-588)1170621554</subfield><subfield code="4">aut</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">B:DE-101</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://d-nb.info/1135208425/04</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">DNB Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=030547079&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-030547079</subfield></datafield></record></collection> |
| id | DE-604.BV045157516 |
| illustrated | Illustrated |
| indexdate | 2024-07-10T08:10:16Z |
| institution | BVB |
| isbn | 9783837415438 |
| language | German |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-030547079 |
| oclc_num | 991852773 |
| open_access_boolean | |
| owner | DE-578 |
| owner_facet | DE-578 |
| physical | 79 Seiten Illustrationen, Diagramme 25 cm |
| publishDate | 2017 |
| publishDateSearch | 2017 |
| publishDateSort | 2017 |
| publisher | UNI-MED Verlag AG |
| record_format | marc |
| series2 | UNI-MED science |
| spelling | Sinzinger, Helmut 1948-2020 (DE-588)115161708 aut edt Lipidtherapie in der Praxis Lipidtherapie in der Praxis - was kann man, muss man, soll man? Prof. Dr. Helmut F. Sinzinger, Prof. Dr. Kurt Derfler, Prim. Priv.-Doz. Dr. Robert Berent ; unter Mitarbeit von Prof. Dr. Stylianos Kapiotis [und 5 andere] 2. Auflage Bremen ; London ; Boston UNI-MED Verlag AG 2017 79 Seiten Illustrationen, Diagramme 25 cm txt rdacontent n rdamedia nc rdacarrier UNI-MED science Lipidstoffwechselstörung (DE-588)4035876-8 gnd rswk-swf Therapie (DE-588)4059798-2 gnd rswk-swf Lipidstoffwechselstörung (DE-588)4035876-8 s Therapie (DE-588)4059798-2 s DE-604 Derfler, Kurt Verfasser (DE-588)1170621104 aut Berent, Robert Verfasser (DE-588)1170621554 aut B:DE-101 application/pdf http://d-nb.info/1135208425/04 Inhaltsverzeichnis DNB Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=030547079&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Sinzinger, Helmut 1948-2020 Derfler, Kurt Berent, Robert Lipidtherapie in der Praxis - was kann man, muss man, soll man? Lipidstoffwechselstörung (DE-588)4035876-8 gnd Therapie (DE-588)4059798-2 gnd |
| subject_GND | (DE-588)4035876-8 (DE-588)4059798-2 |
| title | Lipidtherapie in der Praxis - was kann man, muss man, soll man? |
| title_alt | Lipidtherapie in der Praxis |
| title_auth | Lipidtherapie in der Praxis - was kann man, muss man, soll man? |
| title_exact_search | Lipidtherapie in der Praxis - was kann man, muss man, soll man? |
| title_full | Lipidtherapie in der Praxis - was kann man, muss man, soll man? Prof. Dr. Helmut F. Sinzinger, Prof. Dr. Kurt Derfler, Prim. Priv.-Doz. Dr. Robert Berent ; unter Mitarbeit von Prof. Dr. Stylianos Kapiotis [und 5 andere] |
| title_fullStr | Lipidtherapie in der Praxis - was kann man, muss man, soll man? Prof. Dr. Helmut F. Sinzinger, Prof. Dr. Kurt Derfler, Prim. Priv.-Doz. Dr. Robert Berent ; unter Mitarbeit von Prof. Dr. Stylianos Kapiotis [und 5 andere] |
| title_full_unstemmed | Lipidtherapie in der Praxis - was kann man, muss man, soll man? Prof. Dr. Helmut F. Sinzinger, Prof. Dr. Kurt Derfler, Prim. Priv.-Doz. Dr. Robert Berent ; unter Mitarbeit von Prof. Dr. Stylianos Kapiotis [und 5 andere] |
| title_short | Lipidtherapie in der Praxis - was kann man, muss man, soll man? |
| title_sort | lipidtherapie in der praxis was kann man muss man soll man |
| topic | Lipidstoffwechselstörung (DE-588)4035876-8 gnd Therapie (DE-588)4059798-2 gnd |
| topic_facet | Lipidstoffwechselstörung Therapie |
| url | http://d-nb.info/1135208425/04 http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=030547079&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| work_keys_str_mv | AT sinzingerhelmut lipidtherapieinderpraxis AT derflerkurt lipidtherapieinderpraxis AT berentrobert lipidtherapieinderpraxis AT sinzingerhelmut lipidtherapieinderpraxiswaskannmanmussmansollman AT derflerkurt lipidtherapieinderpraxiswaskannmanmussmansollman AT berentrobert lipidtherapieinderpraxiswaskannmanmussmansollman |
Es ist kein Print-Exemplar vorhanden.
Inhaltsverzeichnis